Spero Therapeutics (SPRO), headquartered in Cambridge’s Central Square neighborhood, announced this week that two government agencies would give the company up to $54.2 million to continue developing a new antibiotic for complicated urinary tract infections. The news came just days after Novartis revealed it would shut down its antibiotics unit and and license out its drug candidates — including one for a complicated urinary tract infection.
Paratek (PRTK), which has offices in Boston and Philadelphia, is working on new antibiotics that are similar to tetracycline. An antibody-drug conjugate against Pseudomonas from Visterra, a company in Waltham, Mass., that Otsuka bought for $430 million, is in the preclinical stage. Entasis Therapeutics, which also has its headquarters in Waltham, is working on antibiotics for several different infections, including gonorrhea.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
